Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
HilleVax, Inc (HLVX)
NASDAQ:HLVX
Holding HLVX?
Track your performance easily
HLVX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.55 - $20.22
Previous Close$1.94
Volume100.68K
Average Volume (3M)205.57K
Market Cap
$96.62M
Enterprise Value-$67.71M
Total Cash (Recent Filing)$189.31M
Total Debt (Recent Filing)$24.97M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 14, 2025EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.09
Shares Outstanding49,806,070
10 Day Avg. Volume147,364
30 Day Avg. Volume205,566
Standard Deviation0.25
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$2.33Price Target Upside21.67% Upside
Rating ConsensusHold
Number of Analyst Covering3
HilleVax, Inc News
PremiumCompany Announcements
HilleVax Reports Q3 Financial Results Amid Strategic Planning
PremiumCompany Announcements
HilleVax, Inc. Clears $26.2M Debt and Ends Loan Agreement
Bulls Say, Bears Say
Bulls Say
Debt ManagementNet Debt to Total Capital is 0%, indicating no debt burden.
Financial PerformanceThe company reported a cash balance of $189.3M, which was 97% above the company’s current market cap of approximately $96M.
Vaccine DevelopmentThe streamlined focus continues to emphasize the potential paths forward for the development of HIL-214 and/or HIL-216 norovirus candidates.
Bears Say
Clinical Trial FailureThe prior Phase 2B NEST-IN1 trial for HIL-214 in norovirus failed to demonstrate effect across both primary and secondary endpoints, resulting in the discontinued development of HIL-214 in infants.
Financial ImpactThe company also incurred a $8.2M impairment charge incorporated into operating expenses which was not previously modeled.
Workforce ReductionThe company management announced an approximately 40% reduction of its workforce to reduce operating expenses.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HLVX FAQ
What was HilleVax, Inc’s price range in the past 12 months?
HilleVax, Inc lowest stock price was $1.55 and its highest was $20.22 in the past 12 months.
What is HilleVax, Inc’s market cap?
Currently, no data Available
When is HilleVax, Inc’s upcoming earnings report date?
HilleVax, Inc’s upcoming earnings report date is Mar 14, 2025 which is in 107 days.
How were HilleVax, Inc’s earnings last quarter?
HilleVax, Inc released its earnings results on Nov 07, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.417 by -$0.103.
Is HilleVax, Inc overvalued?
According to Wall Street analysts HilleVax, Inc’s price is currently Undervalued.
Does HilleVax, Inc pay dividends?
HilleVax, Inc does not currently pay dividends.
What is HilleVax, Inc’s EPS estimate?
HilleVax, Inc’s EPS estimate is -$0.38.
How many shares outstanding does HilleVax, Inc have?
HilleVax, Inc has 49,806,070 shares outstanding.
What happened to HilleVax, Inc’s price movement after its last earnings report?
HilleVax, Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.417. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of HilleVax, Inc?
Among the largest hedge funds holding HilleVax, Inc’s share is Deerfield Management Company, LP. It holds HilleVax, Inc’s shares valued at 3M.
---
HilleVax, Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.33 (21.67% Upside)
$2.33 (21.67% Upside)
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.04%
12-Months-Change
Fundamentals
Return on Equity
-62.24%
Trailing 12-Months
Asset Growth
-39.88%
Trailing 12-Months
Company Description
HilleVax, Inc
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
---
HLVX Stock 12 Month Forecast
Average Price Target
$2.33
▲(21.67% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Fulcrum Therapeutics
―
Immunocore Holdings
―
Revance Therapeutics
―
---